These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25573962)

  • 21. KLF15 in breast cancer: a novel tumor suppressor?
    Yoda T; McNamara KM; Miki Y; Onodera Y; Takagi K; Nakamura Y; Ishida T; Suzuki T; Ohuchi N; Sasano H
    Cell Oncol (Dordr); 2015 Jun; 38(3):227-35. PubMed ID: 25869021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
    Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
    Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of SATB1 protein in the ductal breast carcinoma tissue microarrays - preliminary study.
    Kobierzycki C; Wojnar A; Dziegiel P
    Folia Histochem Cytobiol; 2013; 51(4):333-8. PubMed ID: 24497139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression of stem cell protein Piwil2 and piR-932 in breast cancer.
    Zhang H; Ren Y; Xu H; Pang D; Duan C; Liu C
    Surg Oncol; 2013 Dec; 22(4):217-23. PubMed ID: 23992744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
    Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
    Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
    Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified.
    Lazaris ACh; Chatzigianni EB; Panoussopoulos D; Tzimas GN; Davaris PS; Golematis BCh
    Breast Cancer Res Treat; 1997 Mar; 43(1):43-51. PubMed ID: 9065598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of cyclin kinase subunit 2 in human breast cancer and its prognostic significance.
    Wang J; Xu L; Liu Y; Chen J; Jiang H; Yang S; Tan H
    Int J Clin Exp Pathol; 2014; 7(12):8593-601. PubMed ID: 25674223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers.
    Matsumoto K; Bay BH
    Curr Med Chem; 2021; 28(25):5048-5065. PubMed ID: 33390103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.
    Safwat MD; Habib F; Elayat A; Oweiss N; Reffat S; Algaidi S
    Folia Morphol (Warsz); 2009 Aug; 68(3):144-55. PubMed ID: 19722158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy.
    Amamoto R; Yagi M; Song Y; Oda Y; Tsuneyoshi M; Naito S; Yokomizo A; Kuroiwa K; Tokunaga S; Kato S; Hiura H; Samori T; Kang D; Uchiumi T
    Cancer Sci; 2011 Mar; 102(3):639-47. PubMed ID: 21205079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous programmed cell death in infiltrating duct carcinoma: association with p53, BCL-2, hormone receptors and tumor proliferation.
    Pillai MR; Kesari AL; Chellam VG; Madhavan J; Nair P; Nair MK
    Pathol Res Pract; 1998; 194(8):549-57. PubMed ID: 9779489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
    Zhang Z; Yamashita H; Toyama T; Omoto Y; Sugiura H; Hara Y; Wu X; Kobayashi S; Iwase H
    Breast Cancer Res; 2003; 5(6):R250-6. PubMed ID: 14580261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers.
    Wojnar A; Kobierzycki C; Krolicka A; Pula B; Podhorska-Okolow M; Dziegiel P
    Folia Histochem Cytobiol; 2010 Sep; 48(3):442-6. PubMed ID: 21097442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast.
    Jin H; Ji M; Chen L; Liu Q; Che S; Xu M; Lin Z
    J Exp Clin Cancer Res; 2016 Mar; 35():42. PubMed ID: 26955804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies.
    Jardé T; Caldefie-Chézet F; Goncalves-Mendes N; Mishellany F; Buechler C; Penault-Llorca F; Vasson MP
    Endocr Relat Cancer; 2009 Dec; 16(4):1197-210. PubMed ID: 19661131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance in Ductal Breast Carcinoma.
    Litwin M; Szczepańska-Buda A; Michałowska D; Grzegrzółka J; Piotrowska A; Gomułkiewicz A; Wojnar A; Dzięgiel P; Witkiewicz W
    Anticancer Res; 2018 Apr; 38(4):2021-2030. PubMed ID: 29599319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
    O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
    BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome.
    Hsing CH; Cheng HC; Hsu YH; Chan CH; Yeh CH; Li CF; Chang MS
    Clin Cancer Res; 2012 Feb; 18(3):713-25. PubMed ID: 22186257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.